University of Veterinary Medicine Vienna - Research portal

Diagrammed Link to Homepage University of Veterinary Medicine, Vienna

Willmann Michael,

Presentations at scientific conferences

Presentation

Škor, O; Willmann, M; Fuchs-Baumgartinger, A; Guija de Arespacochaga, A; Kreilmeier-Berger, T; Reháková, K; Tichy, A; Kleiter, M; Schwendenwein, I (2019): Plasma Lactate Dehydrogenase as a Prognostic Marker for Nodal Diffuse Large B-Cell Lymphoma in Dogs. -29th Annual ECVIM-CA Congress; SEP 18-21, 2019; Milano, Italy.

Willmann, M (2019): Mast Cells in Canine Neoplastic Diseases. Working Conference: Classification and Management of Mast Cell Neoplasms in Dogs and Humans: A Comparative Oncology Approach; may 17-18, 2019; Vienna, Austria. 2019.

Willmann, M (2019): Treatment of Advanced Canine Mast Cell Tumors: Recommendations 2019. Working Conference: Classification and Management of Mast Cell Neoplasms in Dogs and Humans: A Comparative Oncology Approach; MAY 17-18, 2019; Vienna, Austria. 2019.

Peter, B; Eisenwort, G; Keller, A; Bauer, K; Berger, D; Sadovnik, I; Stefanzl, G; Hoermann, G; Wolf, D; Racil, Z; Mayer, J; Zuber, J; Sperr, WR; Winter, GE; Willmann, M [and 2 others] (2018): BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, United States, DEC 01-04, 2018. Blood (132): 1722.

Willmann, M (2018): Comparative Oncology Approaches in Mast Cell Neoplasms. Ludwig Boltzmann Cluster Oncology, 10 Year Jubilee ‐ Meeting & Celebration; APR 4, 2018; Vienna, Austria. 2018.

Willmann, M (2018): Leitlinie für die Erstellung klinischer Fallberichte. -VOEK-Jahrestagung 2018, Precongress Day.; SEP 21-23, 2018; Salzburg, Austria.

Willmann, M (2018): Management von Tumoren der Stirnhöhle. 232-232.-VÖK-Jahrestagung 2018; SEP 21-23, 2018; Salzburg, Austria.

Willmann, M (2018): Intranasale Tumoren der Katze – Diagnostik und Therapie. 230-230.-VOEK-Jahrestagung 2018; SEP 21-23, 2018; Salzburg, Austria.

Willmann, M; Kessler, M (2018): Tumoren des Mediastinums - im Teamwork zur Diagnose und Therapie. 236-236.-VOEK-Jahrestagung 2018; SEP 21-23, 2018; Salzburg, Austria.

Eisenwort, G; Peter, B; Sadovnik, I; Blatt, K; Stefanzl, G; Cerny-Reiterer, S; Rülicke, T; Willmann, M; Schwaab, J; Sperr, WR; Reiter, A; Valent, P (2017): Targeting LSC in Patients with advanced SM/MCL. -AUCNM Meeting; OCT 27, 2017; Salzburg, Austria.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2017): Effects of histamine receptor blockers on growth and IgE-dependent histamine release of canine neoplastic mast cells. 64-64.-Veterinary Cancer Society Congress; OCT 26-28, 2017; Portland, United States (USA).

Willmann, M (2017): Mast Cells in Canine Neoplastic Diseases. Comparative Oncology Mast Cell Meeting; MAR 24-25, 2017; Vienna, Austria. 2017.

Willmann, M (2017): Comparative Oncology: Overview, Clinical Implications and Perspectives in the Ludwig Boltzmann Cluster Oncology. KickOff Meeting Vetmeduni Vienna A New Partner of the LBC ONC; AUG 23, 2017; Vienna (VMU), Austria. 2017.

Willmann, M (2017): Mast Cells in Canine Neoplastic Diseases: WP1 Diagnostic Workup, WP2 Therapeutic Algorithms. Comparative Oncology Mast Cell Meeting; MAR 24-25, 2017; Vienna, Austria. 2017.

Blatt, K; Cerny-Reiterer, S; Hölbl, A; Sadovnik, I; Herrmann, H; Herndlhofer, S; Eisenwort, G; Hauswirth, A; Hörmann, G, Willmann, M; Rülicke, T; Sill, H; Sperr, WR; Mannhalter, C; Melo, JV; Jäger, U [and 2 others] (2016): Characterization and target expression profiles of CD34+/CD38− and CD34+/CD38+ stem- and progenitor cells in acute lymphoblastic leukemia (ALL). 8346-8346.-LBG Meeting for Health Sciences; NOV 28-29, 2016; Vienna, AUSTRIA.

Blatt, K; Cerny-Reiterer, S; Schwaab, J; Sotlar, K; Eisenwort, G; Stefanzl, G; Hoermann, G; Mayerhofer, M; Schneeweiss, M; Knapp, S; Rülicke, T; Hadzijusufovic, E; Bauer, K; Smiljkovic, D; Willmann, M [and 3 others] (2016): Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastozytosis. 50-50.-Jahrestagung der DGHO, OeGHO, SGMO und SGH; OCT 15, 2016; Leipzig, GERMANY.

Eisenwort, G; Peter, B; Sadovnik, I; Blatt, K; Stefanzl, G; Cerny-Reiterer, S; Rülicke, T; Willmann, M; Schwaab, J; Sperr, WR; Reiter, A; Valent, P (2016): Identification, characterization and targeting of putative leukemic stem cells in human mast cell leukemia. 8346-8346.-LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2016): Effects of Histamine Receptor 1 antagonists on growth and survival of canine neoplastic mast cells. 8329-8329.-LBG Meeting for Health Sciences.; NOV 28-29, 2016; Vienna, AUSTRIA.

Sadovnik, I; Herrmann, H; Eisenwort, G; Blatt, K; Cerny-Reiterer, S; Rülicke, T; Willmann, M; Herndlhofer, S; Bilban, M; Hörmann, G; Streubel, B; Sperr, WR; Valent, P (2016): Characterization of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem- and progenitor cells in patients with AML and CML. Annual Meeting of the Austrian Society of Haematology and Medical Oncology (OeGHO- & AHOP), Vienna, AUSTRIA, Austria, MAR 17-19, 2016. memo - Magazine of European Medical Oncology 16, 20-21.

Sadovnik, I; Herrmann, H; Hoelbl, A; Cerny-Reiterer, S; Warsch, W; Blatt, K; Peter, B; Hörmann, G; Eisenwort, G; Bilban, M; Sill, H; Sperr, WR; Streubel, B; Willmann, M; Rülicke, M [and 4 others] (2016): Identification of CD25 (IL-2RA) and CD26 (DPPIV) as novel markers and targets in CD34+/CD38− LSC in Ph+ CML. 8460-8460.-LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Valent, P; Willmann, M; Bauer, K; Blatt, K; Sotlar, K; Schwaab, J; Hoermann, G; Hadzijusufovic, E; Reiter, A; Horny, H; Rülicke, T (2016): Preclinical evaluation of CD30 as a novel molecular target in systemic mastocytosis. 170-170.-17th Annual Congress of EUSAAT; AUG 24-27, 2016; Linz, AUSTRIA.

Willmann, M (2016): Vergleichende Onkologie als Brücke zwischen präklinischen Modellen und klinischen Studien. -GV-SOLAS/IGTP-Fortbildungstagung; SEP 1-2, 2016; Vienna, AUSTRIA.

Willmann, M (2016): Canine Mastocytoma: Comparative Oncology Aspects. -Annual Meeting 2016 of the Austrian Competence Network on Mastocytosis (AUCNM): A Partner and Part of the ECNM; SEP 20, 2016; Vienna, AUSTRIA.

Willmann, M (2016): The role of chemo- and immunotherapy in the management of STS – where do we stand today? 29-29.-FECAVA; JUN 23-25, 2016; Vienna, AUSTRIA.

Willmann, M (2016): Systemic treatment of canine STS – state-of-the-art and novel therapies. 29-29.-FECAVA; JUN 23-25, 2016; Vienna, AUSTRIA.

Willmann, M (2016): Management of Canine Mast Cell Tumors – The Patients’ Needs. 21-21.-FECAVA; JUN 23-25, 2016; Vienna, AUSTRIA.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann; M (2015): The Ki-1 antigen (CD30) is a novel target for brentuximab vedotin in neoplastic canine mast cells. -ESVONC Annual Congress; MAY 28-30, 2015 ; Krakow, POLAND.

Eisenwort, G; Peter, B; Blatt, K; Cerny-Reiterer, S; Hoermann, G; Sadovnik, I; Bilban, M; Rülicke, T; Willmann, M; Schwaab, J; Reiter, A; Sperr, WR; Mannhalter, C; Valent, P (2015): Identification and characterization of putative neoplastic stem cells in patients with mast cell leukemia. 20th Congress of European-Hematology-Association, Vienna, AUSTRIA, Austria, JUN 11-14, 2015. Haematologica (100), S1 99-99.

Willmann, M (2015): Wie schreibe ich einen Fallbericht - Leitlinie für das Erstellen klinischer Fallberichte. 1-7.-VÖK VONA Onkologie Seminar Tumorchirurgie ; APR 19, 2015; Wien.

Willmann, M (2015): Übergangsepithelkarzinom der Harnblase - Urethralkarzinom. -VÖK VONA Onkologie Seminar Onkologie des Urogenitaltrakts; NOV 13-14, 2015; Wien.

Willmann, M (2015): Nierentumoren - Eine seltene Tumorerkrankung bei Hund und Katze. -VÖK VONA Onkologie Seminar Onkologie des Urogenitaltrakts ; NOV 13-14, 2015; Wien.

Blatt, K; Cerny-Reiterer, S; Sotlar, K; Schwaab, J; Hoermann, G; Mayerhofer, M; Hadzijusufovic, E; Willmann, M; Reiter, A; Horny, HP; Valent, P (2014): The KI-1 Antigen (CD30) Is A Novel Marker And Potential Therapeutic Target In Advanced Systemic Mastocytosis. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 514-514.

Blatt, K; Cerny-Reiterer, S; Sotlar, K; Schwaab, J; Stefanzl, G; Hoermann, G; Mayerhofer, M; Hadzijusufovic, E; Willmann, M; Reiter, A; Horny, HP; Valent, P (2014): Evaluation of the Ki-1 antigen (CD30) as a novel marker and target in advanced mastocytosis. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 219-220.

Eisenwort, G; Peter, B; Blatt, K; Cerny-Reiterer, S; Hoermann, G; Sadovnik, I; Bilban, M; Rülicke, T; Willmann, M; Schwaab, J; Reiter, A; Sperr, WR; Mannhalter, C; Valent, P (2014): Identification of a putative neoplastic stem cell population in human mast cell leukemia. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 303-303.

Eisenwort, G; Peter, B; Blatt, K; Cerny-Reiterer, S; Hoermann, G; Sadovnik, I; Bilban, M; Rülicke, T; Willmann, M; Schwaab, J; Reiter, A; Sperr, WR; Mannhalter, C; Valent, P (2014): Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia. 56th ASH Annual Meeting & Exposition, San Francisco (CA), USA, United States, DEC 6-9, 2014. Blood (124), 21

Eisenwort, G; Peter, B; Blatt, K; Cerny-Reiterer, S; Hoermann, G; Sadovnik, I; Bilban, M; Rülicke, T; Willmann, M; Schwaab, J; Reiter, A; Sperr, WR; Mannhalter, C; Valent, P (2014): Identification of a neoplastic stem cell in human mast cell leukemia. -56th ASH Annual Meeting & Exposition; DEC 6-9, 2014; San Francisco (CA), USA.

Jensen-Jarolim, E; Fazekas, J; Wang, W; Weichselbaumer, M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Stockner, T; Spillner, E; Kunert, R; Willmann, M; Thalhammer, JG; Inger, J (2014): Comparative oncology: Development of xenogenic vaccines and recombinant antibodies for dog mammary cancer patients. -CSH Asia conference on Tumor Immunology and Immunotherapy.; OCT 28 - NOV 1, 2014; Suzhou, CHINA.

Keller, A; Willmann, M; Valent, P; Hadzijusufovic, E (2014): Evaluation of the JAK2-STAT5 pathway as a therapeutic target in canine mastocytomas. -ECVIM-CA congress; SEP 4-6, 2014; Mainz, GERMANY.

Sadovnik, I; Herrmann, H; Hoelbl, A; Cerny-Reiterer, S; Warsch, W; Blatt, K; Peter, B; Hoermann, G; Eisenwort, G; Bilban, M; Sill, H; Sperr, WR; Streubel, B; Willmann, M; Rülicke, T [and 4 others] (2014): Identification of CD25 (IL-2RA) and CD26 (DPPIV) as novel markers and potential targets on CD34+/CD38- LSC in Ph+ CML. -16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy; SEP 4-7, 2014; Philadelphia, USA.

Singer, J; Fazekas, J; Wang, W; Weichselbaumer, M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Stockner, T; Spillner, E; Kunert, R; Willmann, M; Thalhammer, J; Jensen-Jarolim, E (2014): IgE-based immunotherapy of cancer-A comparative oncology approach. 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, Athens, Greece, Greece, OCT 9-11, 2014. Int J Mol Med (34), S1 S127-S127.

Wedeh, G; Cerny-Reiterer, S; Hadzijusufovic, E; Eisenwort, G; Herrmann, H; Blatt, K; Muellauer, L; Schwaab, J; Bradner, JE; Sperr, WR; Reiter, A; Horny, HP; Willmann, M; Zuber, J; Arock, M; Valent, P (2014): Bromodomain- containing protein 4 (BRD4): a novel therapeutic target in advanced mast cell neoplasms. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 198-199.

Willmann, M (2014): Therapieformen in der Kleintieronkologie - ein Überblick. 61-62.-5.Badener Fortbildungstage ; MAY 14-16, 2014; Baden, AUSTRIA.

Hadzijusufovic, E; Hörmann, G; Peter, B; Herrmann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Mayerhofer, M; Valent, P (2011): Establishment of Novel Mast Cell Lines. -Annual Meeting of European Competence Network on Mastocytosis; NOV 18-19, 2011; Istanbul, TURKEY.

Herrmann, H; Sadovnik, I; Cerny-Reiterer, S; Blatt, K; Ghanim, V; Herndlhofer, S; Hoermann, G; Rülicke, T; Willmann, M; Mitterbauer-Hohendanner, G; Mayerhofer, M; Sperr, WR; Valent, P (2011): The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34(+)/CD38(-)/Lin(-) Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1 alpha. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, San Diego, CA, United States, DEC 10-13, 2011. Blood (118), 21 439-439.

Singer, J; Weichselbaumer, M; Stockner, T; Mechtcheriakova, D; Sobanov, Y; Wrba, F; Horvat, R; Thalhammer, J; Willmann, M; Jensen-Jarolim, E (2011): ErbB-1 and ErbB-2 homologues are expressed in cancer of dog and recognised by cetuximab and trastuzumab antibodies 30th Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Istanbul, TURKEY, Turkey, JUN 11-15, 2011. Allergy (66), S 449-449.

Singer; J, Weichselbaumer, M; Stockner, T; Mechtcheriakova, D; Sobanov, Y; Wrba, F; Horvat, R; Thalhammer, JG; Willmann, M; Jensen-Jarolim, E (2011): ErbB-1 and ErbB-2 homologues are expressed in cancer of dog and recognized by cetuximab and trastuzumab antibodies. -30th Congress of the European Academy of Allergy and Clinical Immuogology; JUN 11-15, 2011; Istanbul, TURKEY.

Willmann, M (2011): Zielgerichtete Krebsmedikamente – TKIs in der tieräztlichen Praxis. 1-14.-Pfizer Fortbildung; FEB 3, 2011; Mauerbach bei Wien, AUSTRIA.

Willmann, M (2011): Medikamentöse Krebsmedikamente – Innovatives praxisnah. -Pfizer Praxis Booster; MAR 16, 2011; Linz, AUSTRIA.

Willmann, M (2011): Medikamentöse Krebsmedikamente – Innovatives praxisnah. -Pfizer Praxis Booster; MAR 9, 2011; Baden, AUSTRIA.

Willmann, M (2011): Die Rote Pfote stellt sich vor: TAH Seminar. 1-12.-26. VÖK-Jahrestagung; SEP 16-18, 2011; Salzburg .

Willmann, M (2011): Primäre und sekundäre Lebertumore – Diagnose und Therapie. 20-27.-18. Royal Canin Diätetik Seminar; JUN 8, 2011; Vienna, AUSTRIA.

Willmann, M (2011): Medikamentöse Krebsmedikamente – Innovatives praxisnah. -Pfizer Praxis Booster; MAR 2, 2011; Mauerbach bei Wien, AUSTRIA.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): NI-1: A Novel Canine Mast Cell Line with a Unique kit Mutation and Resistance against Masatinib. 228-228.-20th ECVIM-CA Congress; SEP 9-11, 2010; Toulouse, FRANCE.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT are Associated with Resistance to Sorafenib, Sunitinib, and Masatinib in Neoplastic Mast Cells. 89-89.-6th PhD Symposium, Medical University Vienna; JUN 16-17, 2010; Vienna, AUSTRIA.

Kleiter, M; Schöps, CA; Tichy, A; Kosik, S; Willmann, M; Pagitz, M; Wolfesberger, B (2010): Installation of a linear accelerator at the University of Veterinary Medicine Vienna. -ACVR-Scientific Meeting; AUG 16-19, 2010; Ashville, NC, USA.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Polo-like kinase 1 (Plk-1) as a novel drug target in canine and human neoplastic mast cells. 228-228.-20th ECVIM-CA Congress; SEP 9-11, 2010; Toulouse, FRANCE.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Identification of Polo-like-kinase-1 (Plk-1) as a novel molecular target in neoplastic mast cells in advanced systemic mastocytosis. -ÖGHO Frühjahrstagung; APR 8-10, 2010; Bregenz, AUSTRIA.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Herrmann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Polo-like kinase-1 (Plk-1) is expressed in neoplastic mast cells and is a potential new target in advanced systemic mastocytosis. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, Berlin, Germany, OKT 1-5, 2010. Onkologie (33), Suppl. 6 206-206.

Singer, J; Weichselbaumer, M; Stockner, T; Mechtcheriakova, D; Sobanov, Y; Wrba, F; Horvat, R; Thalhammer, JG; Willmann, M; Jensen-Jarolim, E (2010): Comparative Oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting. -North German Immunologyday; NOV 12, 2010; Borstel, GERMANY.

Singer, J; Weichselbaumer, M; Stockner, T; Mechtcheriakova, D; Sobanov, Y; Wrba, F; Horvat, R; Thalhammer, JG; Willmann, M; Jensen-Jarolim, E (2010): The ErbB-1 (EGFR) homologue in dog cancer is susceptible to cetuximab targeting. -Annual Meeting of the Austrian Society for Allergology and Immunology; December 3-5, 2010; Vienna, Austria.

Wang, W; Sobanov, Y; Mechtcheriakova, D; Singer, J; Weichselbaumer, M; Willmann, M; Matz, M; Braren, I; Spillner, E; Jensen-Jarolim, E (2010): Generation of Cetuximab-like canine IgE and IgG antibodies for comparative oncology. -28th Symposium of the Collegium Internationale Allergologicum; APR 25-30, 2010; Ischia, ITALY.

Willmann, M (2010): Onkologie in der Tiermedizin - Machbarkeit und Grenzen in der täglichen Praxis. 1-19.-Pfizer Tierärztetag; JUN 12, 2010; Vienna, AUSTRIA.

Willmann, M (2010): Feline Mast Cell Tumours. 95-97.-20th ECVIM-CA Congress; SEP 9-11, 2010; Toulouse, FRANCE.

Hadzijusufovic, E; Peter, B; Willmann, M; Valent, P (2009): Effects of Histamine Recepter Antagonists on Growth and Survival of Neoplastic Mast Cells. -Annual Meeting of European Competence Network on Mastocytosis; NOV 13-14, 2009; Gdansk, POLAND.

Kleiter, M; Wolfesberger, B; Willmann, M; Pagitz, M; Tichy, A (2009): Liposomal doxorubicin and daily fractionated palliative radiotherapy in advanced feline fibrosarcomas. 232-232.-19th annual congress ECVIM; SEP 8-10, 2009; Porto, PORTUGAL.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The BH3 Mimetic Obatoclax induces Apoptosis and Growth Inhibition in Human and Canine Neoplastic Mast Cells. 233-233.-19th ECVIM-CA Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The pan Bcl-2 inhibitor Obatoclax induces apoptosis and growth arrest in neoplastic mast cells in systemic mastocytosis. -7th Congress of the European Competence Network on Mastocytosis (ECNM); NOV 12-13, 2009; Gdansk, POLAND.

Willmann, M (2009): Mammatumoren bei Hunden - vergleichbar mit Brustkrebs bei Menschen?. 3. Interdisziplinäres Symposium: Das Mammakarzinom; OCT 16-17, 2009; Stegersbach, AUSTRIA. 2009.

Willmann, M (2009): Der ältere Hund - Krebs früh erkennen & behandeln. Tiere helfen leben; JAN 31, 2009; Wr. Neustadt, AUSTRIA. 2009.

Willmann, M; Gabner, S; Reifinger, M; Rebuzzi, L; Tichy, A; Thalhammer, JG; Selzer, E (2009): Immunohistochemical detection of vascular endothelial growth factor (VEGF) and c-kit (CD117) in canine melanoma. 233-233.-19th ECVIM-CA Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Wolfesberger, B; Tonar, Z; Witter, K; Willmann, M; Kleiter, M; Pagitz, M; Skalicky, M; Thalhammer, JG; Walter, I (2009): Evaluation of Angiogenesis Markers and Clinical Outcome in Lymphoma Bearing Dogs. 234-234.-ECVIM Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Wolfesberger, B; Willmann, M; Skalicky, M; Kleiter, M; Pagitz, M; Thalhammer, JG (2009): The Velcap-Protocol in Feline Lymphoma: an advisable treatment option?. 27-27.-ESVONC Congress; MAR 27-29, 2009; Visegrad, HUNGARY.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2008): Identifi cation of heat shock protein (Hsp32) as a novel therapeutic target in neoplastic mast cells. ESVONC autumn meeting, Budapest, Hungary, Hungary, 13–15 September, 2007. Vet Comp Oncol (6), 1 84-85.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Konto, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2008): Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Canine Mastocytoma Cells. 28-29.-4th PhD Symposium, Medical University of Vienna; MAY 28-29, 2008; Vienna, AUSTRIA.

Peter, B; Aichberger, KJ; Gleixner, KV; Ferenc, V; Gruze, A; Pickl, WF; Willmann, M; Valent, P (2008): Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax (R)) on Growth and Viability of Canine and Human Neoplastic Mast Cells. 50th Annual Meeting of the American- Society-of-Hematology, San Francisco, CA, United States, DEC 06-09, 2008. Blood (112), 11 318-319.

Peter, B; Aichberger KJ; Gleixner, KV; Ferenc, V; Gruze, A; Pickl, WF; Willmann, M; Valent, P (2008): Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax) on Growth and Viability of Canine and Human Neoplastic Mast Cells. -50th ASH Annual Meeting and Exposition; DEC 6-9, 2008; San Francisco CA, USA.

Sekis, I; Gerner, W; Willmann, M; Rebuzzi, L; Thalhammer, JG; Saalmüller, A; Kleiter, M (2008): Radiation does not enhance vascular endothelial growth factor (VEGF) expression in the canine mastocytoma cell line C2. 54-54.-1st World Vet Cancer Congress / 1st ESVONC/VCS joint meeting; Feb 28 - Mar 1, 2008; Kopenhagen, DENMARK.

Willmann, M (2008): Rote Pfote - Krebsforschung für das Tier, eine interdisziplinäre Herausforderung. 15. Royal Canin Diätetikseminar; AUG 11, 2008; Vienna, AUSTRIA. 2008.

Willmann, M (2008): Der ältere Hund - Krebs frühzeitig erkennen & behandeln. 1-27.-ÖKV-Akademie; OKT 18, 2008; Vienna, AUSTRIA.

Willmann, M; Gabner, S; Nagy, K; Reifinger, M; Rebuzzi, L; Thalhammer, JG; Erovic, B; Selzer, E (2008): Immunohistochemical detection of epidermal growth factor (EGFR) Type I in canine melanoma. 191-191.-18th ECVIM-CA Congress; SEP 4-6, 2008; Ghent, BELGIUM.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R;Gruze, A; Kneidinger, M;Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2007): Identification of Heat Shock Protein (Hsp32) as a Novel Therapeutic Target in Neoplastic Mast Cells. 194--17th ECVIM-CA Congress; Sep 13-15, 2007; Budapest, HUNGARY.

Sekis, I; Willmann, M; Rebuzzi, L; Gerner, W; Käser, T; Thalhammer, JG; Saalmüller, A; Kleiter, M (2007): Radiation Enhances Vascular Endothelial Growth Factor (Vegf) Expression In The Canine Mastocytoma Cell Line C2. -European Society Of Veterinary Oncology, Spring Meeting.; März 23-25, 2007; Cambridge, UK.

Willmann, M (2007): Paraneoplastisches Syndrom in der Kleintieronkologie. Wissenschaftliche Sitzung der ÖGT; Nov 29, 2007; Vienna, AUSTRIA. 2007.

Willmann, M (2007): Interaktive Fälle. 2. VÖK Case Report Seminar; APR 14, 2007; Gmunden, AUSTRIA. 2007.

Willmann, M (2007): Internistische Fallberichte zur Diskussion: Innere Medizin: Anamnese, Klinik, Befunde, Diagnose, Differentialdiagnose, Therapie und Verlauf. 2. VÖK-Case Report Seminar in Toscana Congress; Apr 14, 2007; Gmunden, AUSTRIA. 2007.

Willmann, M; Rebuzzi, L; Sonneck, K; Gleixner, K; Florian, S; Kondo, R; Mayerhofer, M; Gruze, A; Pickl, WF; Valent, P (2007): Detection of VEGF and VEGF receptors in canine mastocytomas. Mast Cell Symposium, AKH; Mai 2-3, 2007; Vienna, AUSTRIA. 2007.

Willmann, M; Schwendenwein, I; Wolfesberger, B; Kleiter, M. Guija de Arespacochaga, A; Valent, P (2007): Unexpected long term survival in a canine AML patient treated with a high dose chemotherapy protocol without bone marrow transplantation: a case report. 34-34.-ESVONC Spring Meeting; 01.-02.04.2007; Ljubljana.

Guija de Arespacochaga, A; Gerner, W; Wolfesberger, B; Saalmüller, A; Willmann, M; Schwendenwein, I (2006): Co-Expression of CD3 and CD79a in canine lymphomas. 120-120.-Annual Meeting ESVCP/ECVCP; 06.09.-08.09.2006; Cambridge.

Guija de Arespacochaga, A; Willmann, M; Gerner, W; Schwendenwein, I (2006): Acute lymphocytic leukaemia causing mild lymphocytosis in a dog tested positive for Ehrlichia phagozytophilum. 114-114.-Annual Meeting EXVCP/ECVCP; 06.09.-08.09.2006; Cambridge.

Rebuzzi, L; Sonneck, K; Agis, H; Vales, A; Kondo, R; Mayerhofer, M; Gruze, A; Pickl, WF; Willmann, M; Valent, P (2006): Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (KDR) in neoplastic mast cells. 23--ESVONC Spring Meeting; Apr 1-2, 2006; Slovenia.

Rebuzzi, L; Sonneck, K; Agis, H; Vales A; Kondo, R; Mayerhofer, M; Gruze, A; Pickl, WF; Willmann, M; Valent, P (2006): Identification of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR in canine neoplastic mast cells. -ÖGHO Frühjahrstagung; APR 27-29, 2006; Wels, AUSTRIA.

Rebuzzi, L; Willmann, M; Sonneck, K; Gleixner, KV; Florian, S; Kondo, R; Mayerhofer, M; Vales, A; Gruze, A; Pickl, WF, Thalhammer JG; Valent, P (2006): Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. -XXV EAACI Congress 2006; JUN 10-14, 2006; Vienna, AUSTRIA.

Willmann, M (2006): Interaktive Fälle. VÖK Case Report Seminar; APR 8, 2006; Gmunden, AUSTRIA. 2006.

Willmann, M (2006): Diagnostik und Therapie häufig vorkommender Tumoren; Paraneoplastische Syndrome; interaktive Fälle. VÖK Onkologie Seminar 1; OCT 28-29, 2006; Vienna, AUSTRIA. 2006.

Willmann, M; Guija, A; Wolfesberger, B; Müllauer, L (2006): The value of anti – PAX5 immunostaining in paraffin-embedded sections of canine lymphomas. A novel (pan pre-B) and B-cell marker. 108--26th Annual VCS Conference ; Oct 19-22, 2006; Georgia, USA.

Willmann, M; Schwendenwein, I; Paschke, P; Jansen, B; Selzer, E (2006): NVX-207, a novel anti-cancer treatment option: susscessful therapy of recurrences of a squamous cell carcinoma and a soft tissue sarcoma after radiotherapy, surgery and chemotherapy: two case studies in dogs. 33--ESVONC Spring Meeting; Apr 1-2, 2006; Slovenia.

Willmann, M; Schwendenwein, I; Paschke, P; Jansen, B; Selzer, E (2006): NVX-207, a novel anti-cancer treatment option: promising responses in a recurring squamous cell carcinoma and soft tissue sarcoma after extensive primary therapy: two case studies in dogs. -26th Annual VCS Conference; OCT 19-22, 2006; Georgia, USA.

Willmann, M; Schwendenwein, I; Wolfesberger, B; Kleiter, M; Guija, A; Valent, P (2006): Unexpected long term survival in a canine AML patient treated with a high dose chemotherapy protocol without bone marrow transplantation. A case report. 34--ESVONC Spring Meeting ; April 1-2, 2006; Slovenia.

Willmann, M; Schwendenwein, I; Wolfesberger, B; Kleiter, M; Guija, A; Valent, P (2006): Unexpected long term survival in a canine AML patient treated with a high dose chemotherapy protocol without bone marrow transplantation. A case report. -26th Annual VCS Conference; OCT 19-22, 2006; Georgia, USA.

Wolfesberger, B; Guija de Arespacochaga, A; Willmann, M; Schwendenwein, I; Gerner, W; Miller, I; Egerbacher, M; Kleiter, M; Thalhammer, JG; Walter, I (2006): Vascular endothelial growth factor and its receptors in lymphomas of dogs. 172-172.-16. ECVIM-CA Congress; 14.-16.09.2006; Amsterdam.

Rebuzzi, L; Sonneck, K; Agis, H; Vales, A; Thalhammer, JG; Willmann, M; Valent, P (2005): Phenotypic and functional characterization of the C2 dog mastocytoma cell line. 76-77.-Annual Meeting of the Austrian Society for Allergology and Immunology (ÖGAI); DEC 1-3, 2005; Vienna, AUSTRIA.

Rebuzzi, L; Sonneck, K; Agis, H; Vales, A; Willmann, M; Valent, P (2005): Immunophenotypic characterization and target profile of the canine mastocytoma cell line C2. -25th Annual VCS Conference; OCT 20-23, 2005; Huntington Beach, USA.

Willmann, M (2003): Diagnostik und Therapie häufig vorkommender Tumoren; Tumoren endokriner Organe; interaktive Fälle. VÖK Onkologie Seminar 2; NOV 23-24, 2003; Vienna, AUSTRIA. 2003.

Gille, L; Kleiter, M; Willmann, M; Nohl, H (2002): Ceruloplasmin, transferrin and ascorbate free radicals as markers of oxidative stress during doxorubicin chemotherapy. 43. Frühjahrstagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, Mainz, Germany, Germany, MAR 12-14, 2002. Naunyn-Schmiedeberg's Archives of Pharmacology (365), S1 R152-R152.

Henninger, W; Probst, A; Willmann, M (1999): Imaging the normal pancreas in the pig used as a role model in experimental medicine. Annual Meeting of the European Association of Veterinary Diagnostic Imaging, Bälsta, Sweden, AUG 26-29, 1998. Veterinary Radiology and Ultrasound (40), 2 190-191.

Probst, A; Henninger, W; Willmann, M (1998): CT-Anatomie des Pankreas beim Schwein als Versuchstier in der Humanmedizin. 20. Alpenländisches Anatomentreffen, Kötschach-Mauthen, Austria, Austria, May 21-23, 1998. Annals of Anatomy (181), 2 151-151.

Poster

Eisenwort, G; Keller, A; Willmann, M; Sadovnik, I; Georg, G; Gleixner, KV; Ivanov, D; Berger, D; Stefanzl, G; Winding, C; Hoermann, G; Sperr, WR; Sill, H; Bettelheim, P; Geissler, K [and 3 others] (2019): Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, DEC 07-10, 2019. Blood (134), S1

Eisenwort, G; Keller, A; Willmann, M; Sadovnik, I; Greiner, G; Gleixner, KV; Ivanov, D; Berger, D; Stefanzl, G; Winding, C; Hoermann, G; Sperr, WR; Sill, H; Bettelheim, P; Geissler, K [and 3 others] (2019): Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). 61st annual ASH meeting and exhibition; Dec 7-10, 2019; Orlando, Florida, United States (USA). 2019.

Eisenwort, G; Peter, B; Sadovnik, I; Schwaab, J; Jawhar, M; Keller, A; Stefanzl, G; Blatt, K; Hoermann, G; Bilban, M; Willmann, M; Winding, C; Sperr, WR; Arock, M; Rülicke, T [and 2 others] (2018): Pharmacologic Targeting of Neoplastic Stem Cells in Human Mast Cell Leukemia. -23rd annual EHA Congress; JUN 14-17, 2018; Stockholm, Sweden.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Hoermann, G; Reifinger, M; Pirker, A; Valent, P; Willmann M (2016): The Ki-1 antigen (CD30), a novel target in neoplastic canine mast cells, is downregulated by interleukin-4. -LBG Meeting for Health Sciences 2016; NOV 28-29, 2016; Vienna, AUSTRIA.

Gamperl, S; Stefanzl, G; Willmann, M; Valent, P; Hadzijusufovic, E (2016): Effects of Histamine Receptor Antagonists on Canine Neoplastic Mast Cells. 205-205.-ESVCP - ESVONC Congress; OCT 20-22, 2016; Nantes, FRANCE.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann, M (2015): The Ki-1 antigen (CD30), a novel target in neoplastic canine mast cells, is downregulated by interleukin-4. -Frühjahrstagung der OeGHO & AHOP; APR 23-25, 2015; Salzburg, AUSTRIA.

Bauer, K; Hadzijusufovic, E; Cerny-Reiterer, S; Pirker, A; Reifinger, M; Valent, P; Willmann, M. (2015): Interleukin-4 modulates expression of CD30 in neoplastic canine mast cells. -Veterinary Cancer Society; OCT 15-17, 2015; Vienna, VA, USA.

Fazekas, J; Rami-Mark, C; Singer, J; Willmann, M; Andreae, F; Wadsak, W; Mitterhauser, M; Jensen-Jarolim, E (2015): Radiolabeling and in vitro evaluation of a recombinant canine anti-cancer IgG. Congress of the European-Academy-of-Allergy-and-Clinical-Immunology, Barcelona, SPAIN, Spain, JUN 06-10, 2015. Allergy (70), S 566-566.

Fazekas, J; Rami-Mark, C; Singer, J; Willmann, M; Andreae, F; Wadsak, W; Mitterhauser, M; Jensen-Jarolim, E (2015): Radiolabeling and in vitro evaluation of a recombinant canine anti-cancer IgG. 104646--EAACI ; JUN 6, 2015; EAACI Online Library.

Haeusler, D; Pagitz, M; Tschokert, M; Willmann, M; Sommer, J; Kappel, S; Wadsak, W; Hacker, M; Mitterhauser, M (2015): [Tc-99m]ZOL - First in vivo imaging in dogs. 21st International Symposium on Radiopharmaceutical Sciences, Columbia, Missouri, USA, United States, May 26-31, 2015. J Labelled Compd Rad (58) S378-S378.

Rami-Mark, C; Fazekas, J; Singer, J; Willmann, M; Wadsak, W; Jensen-Jarolim, E; Mitterhauser, M (2015): A 99mTc-labeled antibody for the dog EGF-receptor - a preclinical evaluation. 21st International Symposium on Radiopharmaceutical Sciences, Columbia, Missouri, USA, United States, May 26-31, 2015. J Labelled Compd Rad (58) S363-S363.

Fazekas, J; Singer, J; Wang, W; Weichselbaumer, M; Mader, A; Matz, M; Steinfellner, W; Sobanov, Y; Mechtcheriakova, D; Willmann, M; Spillner, E; Kunert, R; Jensen-Jarolim, E (2014): Can225IgG, a new canine anti-EGFR antibody. -Austrian Society for Allergology and Immunology Jahrestagung 2014; NOV 6-8, 2014; Salzburg, AUSTRIA.

Fazekas, J; Singer, J; Wang, W; Weichselbaumer, M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Willmann, M; Stockner, T; Spillner, E; Kunert, R; Jensen-Jarolim, E (2014): Can225IgG, the first 'caninised' antibody against EGFR is highly effective in mediating tumor cell growth inhibition and phagocytosis in vitro. European-Academy-of-Allergy-and-Clinical-Immunology Congress, Copenhagen, DENMARK, Denmark, JUN 07-11, 2014. Allergy (69), S99 533-533.

Fazekas, J; Singer, J; Wang, W; Weichselbaumer, M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Willmann, M; Stockner, T; Spillner, E; Kunert, R; Jensen-Jarolim, E (2014): Generation of the first caninized immunotherapeutic antibody for the treatment of EGFR-positive canine cancer. -10th YSA Symposium 2014; JUN 11-12,2014; Vienna, AUSTRIA.

Fazekas, J; Singer, J; Wang, W; Weichselbaumer, M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Willmann, M; Stockner, T; Spillner, E; Kunert, R; Jensen-Jarolim, E (2014): Can225IgG, the first “caninized“ antibody against EGFR is highly effective in mediating tumor cell growth inhibition and phagocytosis in vitro. -EAACI 2014 : European Academy of Allergy and Clinical Immunology Congress 2014; JUN 7-11, 2014; Copenhagen, DENMARK.

Fazekas, J; Singer, J; Wang, W; Weichselbaumer, M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Willmann, M; Stockner, T; Spillner, E; Kunert, R; Jensen-Jarolim, E (2014): Can225IgG, a monoclonal antibody targeting EGFR for veterinary oncology. 19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine, Athens, Greece, Greece, OCT 9-11, 2014. Int J Mol Med (34), S1 S128-S128.

Fazekas, J; Singer, J; Wang, W; Wichselbaumer, M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Willmann, M; Stockner, T; Spillner, E; Kunert, R; Jensen-Jarolim, E (2014): Can225IgG, a monoclonal antibody targeting EGFR for veterinary oncology. -19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine; OCT 9-11, 2014; Athens, GREECE.

Fazekas, J; Willmann, M; Weichselbaumer, M; Singer, J; Pagitz, M; Stark,l P; Knittelfelder, R; Thell, K; Willensdorfer, A; Thalhammer, JG; Jensen-Jarolim, E (2014): A phase I/II xenogeneic CEA vaccination study in canine mammary carcinoma patients. -5th Retreat Center for Pathophysiology, Infectiology and Immunology, meduni Vienna; SEP 17, 2014; Vienna, AUSTRIA.

Flickinger, I; Wolfesberger, B; Pagitz, M; Willmann, M; Kleiter, M (2014): Adjuvant Immunotherapy for canine malignant melanoma patients with ONCEPT TM: A single center experience. 23. ECVIM Congress, Liverpool, UNITED KINGDOM, United Kingdom, SEP 12-14, 2013. Journal of Veterinary Internal Medicine (12), 1 e7.

Flickinger, I; Wolfesberger, B; Pagitz, M; Willmann, M; Kleiter, M (2014): Adjuvante Immunotherapie für canine maligne Melanompatienten mit OnceptTM: Erste Patientencohorte. VÖK Jahrestagung 2014; SEP 19-21, 2014; Salzburg, AUSTRIA. 2014.

Kleiter, M; Moser, M; Flickinger, I; Pagitz, M; Willmann, M; Tichy, A; Wolfesberger, B (2014): Radiotherapy in the treatment of 32 canine subcutaneous soft tissue sarcomas. -ECVIM-Ca congress; Sept 4-6, 2014; Mainz, Germany.

Kleiter, M; Pernkopf, C; Tichy, A; Flickinger, I; Pagitz, M; Willmann, M; Kosik, S; Wolfesberger, B (2014): First patient cohort of canine nasosinal tumors treated with radiotherapy at the University of Veterinary Medicine Vienna. 106--ESVONC congress; Mai 22-24, 2014; Vienna, Austria.

Peter, B; Blatt, K; Herrmann, H; Stefanzl, G; Gleixner, KV; Hadzijusufovic, E; Sperr, WR; Schwaab, J; Willmann, M; Reiter, A; Valent, P (2014): The Multikinase Inhibitor R763/AS703569 Blocks Stat5 Activity And Induces Apoptosis In Neoplastic Human Mast Cells. 19th Congress of the European-Hematology-Association, Milan, ITALY, Italy, JUN 12-15, 2014. Haematologica (99), S1 126-126.

Peter, B; Blatt, K; Herrmann, H; Stefanzl, G; Gleixner, KV; Hadzijusufovic, E; Sperr, WR; Schwaab, J; Willmann, M; Reiter, A; Valent, P (2014): Effects of the multikinase inhibitor R763/AS703569 on growth and survival of neoplastic mast cells. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Hamburg, Germany, Germany, OCT 10-14, 2014. Oncol Res Treat (37), S5 285-285.

Rami-Mark, C; Fazekas, J; Singer, J; Willmann, M; Wadsak, W; Jensen-Jarolim, E; Mitterhauser, M (2014): A 99mTc-labelled antibody for the canine EGF-Receptor: radiolabelling, quality control, stability testing and binding studies. Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Gothenburg, SWEDEN, Sweden, OCT 18-22, 2014. Eur J Nucl Med Mol I (41), S2 S446-S446.

Singer, J; Fazekas, J; Wang, W; Weichselbaumer; M; Matz, M; Mader, A; Steinfellner, W; Meitz, S; Mechtcheriakova, D; Sobanov, Y; Stockner; T; Spillner, E; Kunert, R [and 3 others] (2014): IgE-based Immunotherapy of Cancer – A Comparative Oncology Approach. -19th World Congress on Advances in Oncology and 17th International Symposium on Molecular Medicine; OCT 9-11, 2014; Athens, GREECE.

Blatt, K; Herrmann, H; Willmann, M; Cerny-Reiterer, S; Sadovnik, I; Herndlhofer, S; Streubel, B; Rabitsch, W; Sperr, W; Rulicke, T; Valent, P (2013): Campath-1 (CD52): A novel target in Neoplastic Stem Cells (NSC) in 5q-patients with MDS or AML. Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Vienna, AUSTRIA, Austria, OCT 18-19, 2013. Onkologie (36), S7 286-286.

Blatt, K; Herrmann, H; Willmann, M; Cerny-Reiterer, S; Sadovnik, I; Herndlhofer, S; Streubel, B; Rabitsch, W; Sperr, W; Rülicke, T; Valenti, P (2013): Identification Of Campath-1 (CD52) As A Drug Target In Neoplastic Stem Cells In 5Q-Patients With MDS Or AML. 18th Congress of the European Hematology Association, Stockholm, Sweden, June 13–16, 2013. Haematologica (98), S1 76-76.

Flickinger, I; Wolfesberger, B; Pagitz, M; Willmann, M; Kleiter, M (2013): Adjuvant immunotherapy for canine malignant melanoma patients with ONCEPT TM: a single-center experience. -23.ECVIM-Congress; SEP 12-14, 2013; Liverpool, UNITED KINGDOM.

Oida, K; Hadzijusufovic, E; Panakova, L; Roth-Walter, F; Singer, J; Fazekas, J; Willmann, M; Szalai, K; Tanaka, A; Matsuda, H; Jensen-Jarolim, E (2013): House dust mite allergens induce IgE-independent activation of canine mast cells NI-1. World Allergy and Asthma Congress of the European-Academy-of-Allergy-and-Clinical-Immunology and World-Allergy-Organization, Milan, ITALY, Italy, JUN 22-26, 2013. Allergy (68) 669-669.

Jensen-Jarolim, E; Singer, J; Weichselbaumer, M; Willmann, M; Thalhammer, J (2011): Comparative medicine to speed up drug development. -45 Annual Meeting of the Austrian Society of Tropical Medicine and Parasitology; NOV 15-17, 2011; Vienna, AUSTRIA.

Weichselbaumer, M; Singer, J; Stockner, T; Mechtcheriakova, D; Sobanov, Y; Bajna, E; Wrba, F; Horvat, R; Thalhammer, JG; Willmann, M; Jensen-Jarolim, E (2011): ErbB-1 and ErbB-2 overexpression in canine mammary cancer and their role as targets in comparative oncology. -2nd AACR International Conference on Frontiers in Basic Cancer Research; SEP 14-18, 2011; San Francisco, USA .

Weichselbaumer, M; Willmann, M; Reifinger, M; Singer, J; Bajna, E; Sobanov, Y; Mechteriakova, D; Selzer, E; Thalhammer, JG; Kammerer, R; Jensen-Jarolim, E (2011): Comparative analysis of the target of anti-human carcinoembryonic antigen (CEA) antibody Col-1 and CEA receptor (CEAR) in canine and human mammary cancer. -Annual Congress of the European Society of Veterinary Oncology; MAR 24-26, 2011; Glasgow, UK.

Weichselbaumer, M; Willmann, M; Reifinger, M; Singer, J; Bajna, E; Sobanov, Y; Mechteriakova, D; Selzer, E; Thalhammer, JG; Kammerer, R; Jensen-Jarolim, E (2011): Carcinoembryonic antigen: challenging biomarker in comparative medicine. -45. Austrian Society of Tropical Medicine and Parasitology; NOV 17-19, 2011; Vienna, AUSTRIA.

Flickinger, I; Rütgen, B; Gerner, W; Willmann, M; Saalmüller, A; Kleiter, M (2010): The effect of radiation on VEGF and VEGF recepter expression in the canine melanoma cell line TLM1. -Annual VCS Conference; OCT 29-NOV 1, 2010; San Diego, CA, USA.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines. 15th Congress of the European Hematology Association, Barcelona, SPAIN, Spain, JUN 10-14, 2010. Haematologica (95), S2 357-357.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): KIT Mutations Predict Resistance to Sorafenib, Sunitinib, and Masatinib in Neoplastic Human and Canine Mast Cells. 17-17.-Frühjahrstagung der ÖGHO und der AHOP; APR 8-10, 2010; Bregenz, AUSTRIA.

Hadzijusufovic, E; Peter, B; Hermann, H; Schuch, K; Thaiwong, T; Yuzbasiyan-Gurkan, V; Pickl, WF; Willmann, M; Valent, P (2010): Mutations in KIT Predict Resistance to Several TKI (Sorafenib, Sunitinib, and Masatinib) in Neoplastic Human and Canine Mast Cell Lines. 357-357.-15th Congress of the European Hematology Association; JUN 10-14, 2010; Barcelona, SPAIN.

Peter, B; Gleixner, K; Cerny-Reiterer, S; Herrmann, H; Hadzijusufovic, E; Ferenc, V; Winter, V; Schuch, K; Willmann, W; Pickl, W; Valent, P (2010): Identification Of Polo-Like Kinase-1 (Plk-1) As A Novel Drug Target In Neoplastic Mast Cells In Systemic Mastocytosis. 15th Annual Meeting of the European-Hematology-Association, Barcelona, SPAIN, Spain, JUN 10-13, 2010. Haematol-Hematol J (95), Suppl. 2 0446.

Peter, B; Gleixner, KV; Cerny-Reiterer, S; Hermann, H; Hadzijusufovic E; Ferenc, V; Winter, V; Schuch, K; Willmann, M; Pickl, WF; Valent, P (2010): Identification of Polo-like kinase-1 (Plk-1) as a novel drug target in neoplastic mast cells in systemic mastocytosis. 357-357.-15th Congress of the European Haematology Association; JUN 10-13, 2010; Barcelona, SPAIN.

Peter, B; Herrmann, H; Gleixner, KV; Hadzijusufovic, E; Laffer, S; Schuch, K; Pickl, W; Sarno, SM; Willmann, M; Valent, P (2010): The Aurora Kinase Inhibitor R763/AS703569 Exerts Major Growth Inhibitory and Apoptosis Inducing Effects on Neoplastic Mast Cells. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando, FL, DEC 04-07, 2010. Blood (116), 21 1620-1620.

Wang, W; Sobanov, Y; Mechtcheriakova, D; Singer, J; Weichselbaumer, M; Willmann, M; Matz, M; Braren, I; Spillner, E; Jensen-Jarolim, E (2010): Construction of vectors generating Cetuximab-like canine IgE and IgG antibodies for comparative oncology. -14th International Congress of Immunology; AUG 22-27, 2010; Kansai, JAPAN.

Weichselbaumer, M; Singer, J; Bajna, E; Mechtcheriakova, D; Horvat, R; Thalhammer, JG; Willmann, M; Jensen-Jarolim, E (2010): Expression of ErbB-1 and ErbB-2 homologues in cancer of dog (Canis lupus familiaris) and their recognition by cetuximab (Erbitux ®) and trastuzumab (Herceptin ®) antibodies. -6th PhD-Symposium, Young Scientist Association of the Medical University of Vienna; JUN 16-17, 2010; Vienna, AUSTRIA.

Weichselbaumer, M; Willmann, M; Reifinger, M; Singer, J; Bajna, E; Sobanov, Y; Mechteriakova, D; Selzer, E; Thalhammer, JG; Kammerer, R; Jensen-Jarolim, E (2010): Comparative analysis of CEACAMs and CEACAM receptor (CEAR) in mammary cancer of humans versus dog (Canis lupus familiaris). -Annual Meeting of the Austrian Society for Allergology and Immunology; DEC 3-5, 2010; Vienna, Austria.

Hadzijusufovic, E; Gleixner, KV; Peter, B; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The H1 Receptor Antagonists Terfendine and Loratadine inhibit Growth and induce Apoptosis in Neoplastic Mast Cells. Annual Meeting of the Austrian Society of Haematology and Oncology, Salzburg, AUSTRIA, Austria, APR 16-18, 2009. memo - Magazine of European Medical Oncology (2), S 2 6-6.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Gleixner, KV; Gruze, A; Kneidinger, M; Thaiwong, T; Pickl, WF; Yuzbasiyan-Gurkan, V; Willmann, M; Valent, P (2009): Antiproliferative Effects of Four Tyrosine Kinase Inhibitors on Neoplastic Feline Mast Cells Exhibiting a kit Exon-8 ITD Mutation. 267-267.-19th ECVIM-CA Congress; SEP 8-10, 2009; Porto, PORTUGAL.

Peter, B; Aichberger, K; Gleixner, KV; Hadzijusufovic, E; Schuch, K; Pickl, WF; Willmann, M; Valent, P (2009): The Bh3 Mimetic Gx015-070 (Obatoclax) Induces Apoptosis And Growth Inhibition In Neoplastic Mast Cells. 14th Annual Meeting of the European-Hematology-Association, Berlin, GERMANY, Germany, JUN 04-07, 2009. Haematol-Hematol J (94), Suppl. 2 305.

Peter, B; Aichberger, KJ; Gleixner, KV; Hadzijusufovic, E; Gruze, A; Pickl, WF; Willmann, M; Valent, P (2009): The BH3 Mimetic GX015-070 (Obatoclax) induces Apoptosis and Growth Inhibition in Neoplastic Mast Cells. -14th Congress of the European Hematology Association; JUN 4-7, 2010; Berlin, GERMANY.

Peter, B; Hadzijusufovic, E; Schuch, K; Blatt, K; Gleixner, KV; Pickl, WF; Willmann, M; Valent, P (2009): Evaluation of antineoplastic effects of INNO-406 on human and canine neoplastic mast cells. -Frühjahrstagung der ÖGHO und der AHOP; APR 12-14, 2009; Salzburg, AUSTRIA.

Rütgen, BC; Hammer, SE; Gerner, W; Christian, M; Willmann, M; Kleiter, M; Schwendenwein, I; Saalmüller, A (2009): Establishment and characterization of a canine B-cell line derived from a malignant lymphoma. -3rd European Veterinary Immunology Workshop (EVIW 2009); Sept 10-13, 2009; Berlin, GERMANY.

Rütgen, BC; Hammer, SE; Gerner, W; Christian, M; Willmann, M; Kleiter, M; Schwendenwein, I; Saalmüller, A (2009): Establishment and characterization of a novel canine B-cell line derived from a malignant non-Hodgkin’s lymphoma. 64--Annual Congress of the European Society of Veterinary Oncology (ESVONC 2009); Mar 27-29, 2009; Visegrád, HUNGARY.

Rütgen, BC; Hammer, SE; Gerner, W; Christian, M; Willmann, M; Kleiter, M; Schwendenwein, I; Saalmüller, A (2009): Establishment and characterization of a novel canine B-cell line derived from a malignant non-Hodgkin’s lymphoma. 15-15.-Genes, Dogs and Cancer: 5th International Canine Cancer Conference; Feb 13-15, 2009; Orlando, Florida, USA.

Hadzijusufovic, E; Gleixner, KV; Gruze, A; Kneidinger, M; Baumgartner, C; Pickl, WF; Willmann, M; Valent, P (2008): The H1-Receptor Antagonists Loratadine and Terfenadine inhibit Proliferation and Survival of Neoplastic Mast Cells. 53-53.-ESVONC and VCS First Joint Meeting; FEB 28 - MAR 1, 2008; Copenhagen, DENMARK.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent (2008): Identification of the Tyrosine Kinase Receptor Kit as a Molecular Target in Neoplastic Ferline Mast Cells. 98-98.-28th Annual VCS Conference; OCT 18-21, 2008; Seattle, USA.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent, P (2008): Evaluation of growth-inhibitory effects of kit tyrosine kinase inhibitors on feline neoplastic mast cells. 215-215.-18th ECVIM-CA Congress; SEP 4-6, 2008; Ghent, BELGIUM.

Hadzijusufovic, E; Peter, B; Rebuzzi, L; Baumgartner, C; Gleixner, KV; Gruze, A; Kneidinger, M; Pickl, WF; Willmann, M; Valent, P (2008): Antiproliferative Effects of KIT Tyrosine Kinase Inhibitors in Feline Neoplastic Mast Cells. Frühjahrstagung 2008 der Österreichischen Gesellschaft für Hämatologie und Onkologie und der Arbeitsgemeinschaft hämato-onkologischer Pflegepersonen in Österreich (AHOP), Innsbruck, Austria, Austria, APR 10-12, 2008. Magazine of European Medical Oncology (1), Suppl. 1 10-10.

Rütgen, BC; de Arespacochaga, AG; Wolfesberger, B; Gerner, W; Hammer, SE; Willmann, M; Schwendenwein, I; Saalmüller, A (2008): Staging and diagnosis of non-Hodgkin's lymphoma in dogs - a comparative model for translational lymphoma research. Joint Annual Meeting of Immunology of the Austrian and German Societies (ÖGAI, DGfI), Vienna, Austria, Austria, September 3–6, 2008. Wien Klin Wochenschr (120), Suppl. 185-186.

Rütgen, BC; Guija de Arespacochaga, A; Wolfesberger, B; Gerner, W; Hammer, SE; Willmann, M; Saalmüller, A; Schwendenwein, I (2008): Klassifizierung und Diagnose von non-Hodgkin’s Lymphomen bei Hunden – ein Modell für vergleichende Lymphomforschung. 3. Jahrestagung der Vereinigung Österreichischer Kleintiermediziner (23rd VÖK Annual Congress); September 20-21, 2008; Salzburg, AUSTRIA. 2008.

Hadzijusufovic, E; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Maeda, H; Willmann, M; Valent, P (2007): Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Canine Mastocytoma Cells. ÖGHO und AHOP Frühjahrstagung, Vienna, AUSTRIA, Austria, Apr 12-14, 2007 . Wiener medizinische Wochenschrift / Supplement (157), 121 16.

Hadzijusufovic, EH; Rebuzzi, L; Gleixner, KV; Vales, A; Kondo, R; Gruze, A; Kneidinger, M; Krauth, MT; Samoorapoompichit, P; Greish, K; Mayerhofer, M; Pickl, WF; Hiroshi, M; Willman, M; Valent, P (2007): Identification of heme oxygenase-1 (HO-1=Hsp32) as a novel therapeutic target in canine mastocytoma cells. 12th Congress of the European Hematology Association, Vienna, Austria, Austria, June 7 – 10, 2007 . Haematol-Hematol J (92) 489-490.

Rebuzzi, L; Willmann, M; Sonneck, K; Gleixner, KV; Florian, S; Kondo, R; Mayerhofer, M; Vales, A; Gruze, A; Pickl, WF; Thalhammer, JG; Valent, P (2006): Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. .-26th Annual VCS Conference; OCT 19-22, 2006; Georgia, USA.

Kleiter, M; Gille, L; Willmann, M; Nohl, H (2000): Plasma redox-state in healthy and cancer bearing dogs. An electron spin resonance (ESR) study. 99-99.-20. Annual Conference; 2000; Pacific Grove, California, USA.

Henninger, W; Probst, A; Willmann, M (1998): Imaging the normal pancreas in the pig used as a role model in experimental medicine. 5th Annual Conference of the EAVDI; AUG 26-29, 1998; Balsta, Sweden. 1998.

Presented Poster

Eisenwort, G; Sadovnik, I; Schwaab, J; Jawhar, M; Keller, A; Stefanzl, G; Blatt, K; Hoermann, G; Bilban, M; Willmann, M; Winding, C; Sperr, WR; Arock, M; Rülicke, T; Reiter, A; Valent, P (2018): Pharmacologic Targeting of Leukemic Stem Cells in Mast Cell Leukemia. Ludwig Boltzmann Meeting for Health Sciences; NOV 29, 2018; Vienna, Austria. 2018.

Willmann, M (2005): Der nephrologische Notfall. 2. VÖK-Nephrologieseminar, Erkrankungen der Nieren und der harnableitenden Wege bei Hund und Katze. Internistische und Chirurgische Ansätze, Teil 2, Gmunden, 02.04.2005. 2. VÖK-Nephrologieseminar, Erkrankungen der Nieren und der harnableitenden Wege bei Hund und Katze. Internistische und Chirurgische Ansätze, Teil 2, Gmunden, 02.04.2005.

Kneissl, S; Willmann, M (2004): Braucht der Internist die Bildgebende Diagnostik?. 1. VÖK-Nephrologieseminar, Gmunden, 20.03.2004. 1. VÖK-Nephrologieseminar, Gmunden, 20.03.2004.

Willmann, M (2004): Der onkologische Notfallpatient. VÖK Onkologieseminar Teil III, Wien, Hotel Schloß Wilhelminenberg, Austria, 06.-07.11.2004. VÖK Onkologieseminar Teil III, Wien, Hotel Schloß Wilhelminenberg, 06.-07.11.2004.

Willmann, M (2004): Die Katze als Tumorpatient. VÖK Onkologieseminar Teil III, Wien, Hotel Schloß Wilhelminenberg, Austria, 06.-07.11.2004. VÖK Onkologieseminar Teil III, Wien, Hotel Schloß Wilhelminenberg, 06.-07.11.2004.

Willmann, M (2004): Spezielle Onkologie "Tumoren der Niere und harnableitenden Wege". VÖK Onkologieseminar Teil III, Wien, Hotel Schloß Wilhelminenberg, Austria, 06.-07.11.2004. VÖK Onkologieseminar Teil III, Wien, Hotel Schloß Wilhelminenberg, 06.-07.11.2004.

Willmann, M; Henninger, W; Probst, A (2003): Die Bedeutung der Computertomographie bei der Evaluierung paranasaler Sinuserkrankungen des Pferdes. 3. ÖGT - Pferdetage, Erkrankungen des Respirationstraktes, Salzburg, Austria, 9. 5. - 11.5.2003. 3. ÖGT - Pferdetage, Erkrankungen des Respirationstraktes, Salzburg, 9. 5. - 11.5.2003.

Gille, L; Kleiter, M; Willmann, M; Nohl, H (2002): Paramagnetic species in the plasma of dogs with malignant lymphoma and the influence of doxorubicin chemotherapy. Abstract Book. 12. Symposium der deutschsprachigen Veterinärpharmakologen und ¿toxikologen, Giessen, Germany, Germany, 26.09. ¿ 27.09.2002. 12. Symposium der deutschsprachigen Veterinärpharmakologen und ¿toxikologen, Giessen, Germany, 26.09. ¿ 27.09.2002.

Probst, A; Willmann, M; Henninger, W (2002): Communications of nasal and paranasal cavities in equine CT of normal life controls. 9th Annual Conference of EAVDI, Murcia, Spanien, Spain, 24.07. - 27.07.2002. 9th Annual Conference of EAVDI, Murcia, Spanien, 24.07. - 27.07.2002.

Willmann, M (2002): Grundprinzipien der Chemotherapie. Onkologie in der Tierärztlichen Praxis. Arbeitskreis Veterinärchirurgie (AKVC), Wien, Austria, 20. 4. 2002. Onkologie in der Tierärztlichen Praxis. Arbeitskreis Veterinärchirurgie (AKVC), Wien, 20. 4. 2002.

Willmann, M (2002): Der diabetische Patient; Insulintherapie bei Hund und Katze. Fortbildungsveranstaltung der steirischen Tierärztekammer, Graz, Austria, 12. 6. 2002. Fortbildungsveranstaltung der steirischen Tierärztekammer, Graz, 12. 6. 2002.

Kleiter, M; Luckschander, N; Willmann, M; Kölbl, S; Lutz, H (2001): Imidocarb diproprionate alone or in combination with immunosuppressive therapy for treatment of canine ehrlichiosis. ESVIM-Kongreß (European Society for Veterinary Internal Medicine), Dublin, 5. - 8. 9. 2001. ESVIM-Kongreß (European Society for Veterinary Internal Medicine), Dublin, 5. - 8. 9. 2001.

Willmann, M (2001): Chronische Niereninsuffizienz mit hypertensiver Retinopathie einer Katze. Fallbeispiele und Falldiskussion. Nephrologie-Urologie Seminar, UVW Wien, Austria, 9. 6. 2001. Nephrologie-Urologie Seminar, UVW Wien, 9. 6. 2001.

Willmann, M (2001): Chronische Niereninsuffizienz oder Hypoadrenokortizismus. Fallbeispiele und Falldiskussion. Nephrologie-Urologie-Seminar, UVW Wien, Austria, 9. 6. 2001 . Nephrologie-Urologie-Seminar, UVW Wien, 9. 6. 2001 .

© University of Veterinary Medicine ViennaHelp and DownloadsAccessibility statement